CHD

Researches done on the use of statins during the last two decades have shown conflicting results in their effects on DM, Cardiac, liver and Kidney functions. Six forms of statins are being prescribed as a preventive measure to reduce the incidence of cardiovascular morbidity and mortality; but statin use have also shown alternations in DM, liver and Kidney function. The latest observations relates to cancer prevention/induction. Statins prescriptions are done mostly for elderly patients in order to reduce lipid profile mostly Total cholesterol and LDL levels. Studies have shown that statins use affects muscular function, induce prediabetes, and alter liver enzymes and affects mitochondrial functions. They may also interact with other medications. Some merits shown in the use of statins include prevention of MCI and strokes. Among the statins used, atorvastatin was found to be very beneficial with minimal side effects with greater beneficial function in maintaining other organ functions. This review article highlights the research findings on the use of statins and its merits and demerits during the last two decades. More clinical trials with large population are required to establish the type of statins to be required for each type of patients and clinical conditions.

To assess the prevalence and types of lipid abnormalities, analyze the rationalein the drug therapy and drug interactions in the drug therapy. Each patient’s medication profile was reviewed and patients who met the inclusion criteria were briefed on the study. The data from medical charts of all the cases with lipid abnormality were recorded during ward rounds. The study population included patients with primary dyslipidemia (38.8%) and secondary dyslipidemia (61.2%). The major concomitant disease was systemic hypertension followed by Diabetes Mellitus. Majority of the patients were in non CHD category. 88.7% of non CHD patients had 2+ risk factors and 11.3% had 1 risk factor. The non CHD group were subjected for estimation of 10 year risk percentage for having CHD using Framingham’s scale in which 92% of non CHD patients had ≤ 20% ten year risks for having CHD. The drug interactions with lipid lowering agents were 33.3% and without lipid lowering agents were 66.7%. The major drug interactions with lipid lowering agents were high. Conclusion: Results revealed that Diabetes, Thyroid Disorders, Nephrotic Disorders are responsible for elevation of lipid profiles. Some dyslipidemias appear to be refractory to drug treatment in the presence of an ongoing unrecognized secondary cause.